바이오마커 검사 서비스 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 용도별, 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1.06 billion by 2030, registering a CAGR of 8.59% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

• The biomarker assay development & validation segment by service was expected to hold the largest share of 45.77% in 2024. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
• Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.45% in 2024, owing to the rising investment in R&D by these companies
• North America held the largest share of 46.23% in 2024, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. Type Segment
  • 1.2.4. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
    • 3.2.1.2. Increasing R&D Activities
    • 3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
• 3.3. Biomarker Testing Services Market: Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biomarker Testing Service Market Movement Analysis
• 4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
• 4.4. Biomarker Assay Development & Validation
  • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 4.5. Flow Cytometry
  • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Testing Services Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biomarker Testing Application Market Movement Analysis
• 5.3. Global Biomarker Testing Service Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 5.5. Drug Discovery & Development
  • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Testing Services Market: Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biomarker Testing Services Market Movement Analysis
• 6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Molecular Biomarkers
  • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 6.5. Cellular Biomarkers
  • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biomarker Testing Services Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biomarker Testing Services Market Movement Analysis
• 7.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 7.5. Research Institutes
  • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 7.6. CROs
  • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Scenario
    • 8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Scenario
    • 8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Scenario
    • 8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Scenario
    • 8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Scenario
    • 8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Scenario
    • 8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Scenario
    • 8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Scenario
    • 8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Scenario
    • 8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Scenario
    • 8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Scenario
    • 8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Scenario
    • 8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.3. Japan
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Scenario
    • 8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Scenario
    • 8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Scenario
    • 8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Scenario
    • 8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Scenario
    • 8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.8. Indonesia
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Scenario
    • 8.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.9. Malaysia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Scenario
    • 8.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.10. Singapore
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Scenario
    • 8.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.11. Taiwan
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Scenario
    • 8.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Scenario
    • 8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Scenario
    • 8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Scenario
    • 8.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Scenario
    • 8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Scenario
    • 8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Scenario
    • 8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Scenario
    • 8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.6. Israel
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Scenario
    • 8.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Bio Agilytix Labs
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Eurofins Scientific
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. SGS SA.
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Charles River Laboratories
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. LabCorp
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. ICON Plc
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. IQVIA
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Syneos Health
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Intertek Group Plc
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives